<p>ST Germain D J Co. Inc. 在最近向证券交易委员会的披露中表示，在第三季度将其在 Zimmer Biomet Holdings, Inc. (NYSE:ZBH - 免费报告) 的持股增加了 12.3%。该公司在此期间额外购买了 14,058 股后，持有 127,931 股这家医疗设备供应商的股票。ST Germain D J Co. Inc. 在最近一个季度末持有约 0.06% 的 Zimmer Biomet，价值 12,601,000 美元。</p>
<p>获取 <strong>Zimmer Biomet</strong> 警报：</p>
<ul>
<li>Intuitive Surgical 在机器人手术创新中领先</li>
</ul>
<p>其他大型投资者最近也买卖了该公司的股票。Brighton Jones LLC 在第四季度购买了价值 204,000 美元的 Zimmer Biomet 新头寸。公共部门养老金投资委员会在第一季度将其在 Zimmer Biomet 的持股增加了 11.4%。公共部门养老金投资委员会目前持有 27,284 股这家医疗设备供应商的股票，价值 3,088,000 美元，此前在上个季度又购买了 2,789 股。Russell Investments Group Ltd. 在第一季度将其在 Zimmer Biomet 的持股增加了 13.3%。Russell Investments Group Ltd. 目前持有 82,897 股这家医疗设备供应商的股票，价值 9,362,000 美元，此前在上个季度又购买了 9,758 股。Cresset Asset Management LLC 在第一季度将其在 Zimmer Biomet 的持股增加了 16.2%。Cresset Asset Management LLC 目前持有 43,219 股这家医疗设备供应商的股票，价值 4,902,000 美元，此前在上个季度又购买了 6,011 股。最后，Raymond James Financial Inc. 在第一季度将其在 Zimmer Biomet 的持股增加了 195.5%。Raymond James Financial Inc. 目前持有 594,097 股这家医疗设备供应商的股票，价值 67,240,000 美元，此前在上个季度又购买了 393,077 股。机构投资者持有该公司 88.89% 的股票。</p>
<h2>Zimmer Biomet 股价下跌 1.7%</h2>
<p>周三，NYSE:ZBH 的开盘价为 90.90 美元。该公司的市值为 180.1 亿美元，市盈率为 22.50，市盈增长比率为 2.43，贝塔值为 0.61。该公司的流动比率为 2.43，速动比率为 1.39，债务与股本比率为 0.59。Zimmer Biomet Holdings, Inc. 的 12 个月低点为 85.33 美元，12 个月高点为 114.44 美元。该公司的 50 日简单移动平均线为 95.35 美元，200 日简单移动平均线为 96.73 美元。</p>
<ul>
<li>2 家机器人手术股票挑战 Intuitive Surgical 的领先地位</li>
</ul>
<p>Zimmer Biomet (NYSE:ZBH - 获取免费报告) 最近在 11 月 5 日发布了其财报。这家医疗设备供应商报告本季度每股收益 (EPS) 为 1.90 美元，超出分析师一致预期的 1.88 美元，超出 0.02 美元。Zimmer Biomet 的股本回报率为 12.85%，净利润率为 10.05%。该公司在本季度的收入为 20 亿美元，而分析师预期为 20.1 亿美元。去年同期，该公司的每股收益为 1.74 美元。该公司的季度收入同比增长 9.6%。Zimmer Biomet 已将其 2025 财年的指导目标设定为 8.100-8.300 每股收益。平均而言，股票研究分析师预计 Zimmer Biomet Holdings, Inc. 本年度将发布 8.22 美元的每股收益。</p>
<h2>华尔街分析师观点</h2>
<p>几位股票研究分析师对 ZBH 股票发表了看法。摩根大通重申了对 Zimmer Biomet 的 &#34;中性&#34; 评级，并在 11 月 6 日的研究报告中将目标价下调至 100.00 美元（之前为 115.00 美元）。瑞银集团将 Zimmer Biomet 的目标价从 96.00 美元下调至 88.00 美元，并在 11 月 6 日的报告中对该公司给予了 &#34;卖出&#34; 评级。Canaccord Genuity Group 将 Zimmer Biomet 的目标价从 101.00 美元下调至 93.00 美元，并在 11 月 10 日的研究报告中对该公司给予了 &#34;持有&#34; 评级。巴克莱将 Zimmer Biomet 的目标价从 112.00 美元下调至 105.00 美元，并在 11 月 5 日的研究报告中对该股票给予了 &#34;减持&#34; 评级。最后，Rothschild &amp; Co Redburn 在 9 月 18 日的研究报告中开始覆盖 Zimmer Biomet。他们给予了该公司 &#34;买入&#34; 评级，并设定了 130.00 美元的目标价。一位股票研究分析师对该股票给予了强烈买入评级，七位给予了买入评级，十二位给予了持有评级，二位给予了卖出评级。根据 MarketBeat.com 的数据，Zimmer Biomet 目前的平均评级为 &#34;持有&#34;，平均目标价为 107.50 美元。</p>
<ul>
<li>波士顿科学：为什么这家医疗科技巨头不会放慢脚步</li>
</ul>
<p><strong>查看我们关于 ZBH 的最新报告</strong></p>
<h2>Zimmer Biomet 公司简介</h2>
<p>（免费报告）</p>
<p>Zimmer Biomet Holdings, Inc. 及其子公司在全球范围内作为一家医疗技术公司运营。该公司设计、制造和销售骨科重建产品，如膝关节和髋关节产品；S.E.T. 产品，包括运动医学、生物制剂、足踝、四肢和创伤产品；颅面和胸部产品，包括面部和颅骨重建产品，以及固定和稳定胸部骨骼以促进心脏手术、创伤或胸部畸形后愈合或重建的产品。</p>
<h2>推荐故事</h2>
<ul>
<li>五只我们更看好的股票，胜过 Zimmer Biomet</li>
<li>REIT 股票 - 今天值得加入您投资组合的最佳 REIT 股票</li>
<li>AI 芯片离不开这两家被低估的科技巨头</li>
<li>2022-2025 年股市假期 - 纽约证券交易所和纳斯达克将何时关闭</li>
<li>为什么台湾半导体的 6.5% 下跌可能是一个明智的买入机会</li>
<li>如何使用股票筛选器寻找股票</li>
<li>RTX 在国防订单激增中飙升至创纪录高点</li>
</ul>
<p><strong>想看看其他对 ZBH 持有的对冲基金吗？</strong> 访问 HoldingsChannel.com 获取 Zimmer Biomet Holdings, Inc. (NYSE:ZBH - 免费报告) 的最新 13F 文件和内部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVpCSA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVpCSA"/></p>
<p><em>此即时新闻提醒是由叙事科学技术和来自 MarketBeat 的金融数据生成的，旨在为读者提供最快的报道和公正的覆盖。请将任何关于此故事的问题或评论发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在 Zimmer Biomet 吗？</h2>
<p>在你考虑 Zimmer Biomet 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Zimmer Biomet 并不在名单上。</p>
<p>虽然 Zimmer Biomet 目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

<p>ST Germain D J Co. Inc. 在第三季度增加了对 Zimmer Biomet Holdings 的持股比例，增幅为 12.3%，额外购买了 14,058 股，目前持有 127,931 股，市值为 1260 万美元。Zimmer Biomet 的股票受到多家机构投资者的影响，目前市值为 180.1 亿美元。分析师对该股票的评级不一，普遍共识为 “持有”。该公司报告第三季度每股收益为 1.90 美元，略高于预期，并将 2025 财年的每股收益指引设定在 8.100-8.300 美元</p>

<p>ST Germain D J Co. Inc. increased its position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 12.3% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 127,931 shares of the medical equipment provider's stock after buying an additional 14,058 shares during the period. ST Germain D J Co. Inc. owned about 0.06% of Zimmer Biomet worth $12,601,000 at the end of the most recent quarter.</p>
<div class="lb-trans"><p>ST Germain D J Co. Inc. 在最近向证券交易委员会的披露中表示，在第三季度将其在 Zimmer Biomet Holdings, Inc. (NYSE:ZBH - 免费报告) 的持股增加了 12.3%。该公司在此期间额外购买了 14,058 股后，持有 127,931 股这家医疗设备供应商的股票。ST Germain D J Co. Inc. 在最近一个季度末持有约 0.06% 的 Zimmer Biomet，价值 12,601,000 美元。</p>
</div><p>Get <strong>Zimmer Biomet</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Zimmer Biomet</strong> 警报：</p>
</div><ul>
<li>Intuitive Surgical Leads the Pack in Robotic Surgery Innovation</li>
</ul>
<div class="lb-trans"><ul>
<li>Intuitive Surgical 在机器人手术创新中领先</li>
</ul>
</div><p>Other large investors also recently bought and sold shares of the company. Brighton Jones LLC bought a new position in shares of Zimmer Biomet in the 4th quarter worth $204,000. Public Sector Pension Investment Board raised its holdings in Zimmer Biomet by 11.4% in the first quarter. Public Sector Pension Investment Board now owns 27,284 shares of the medical equipment provider's stock worth $3,088,000 after purchasing an additional 2,789 shares in the last quarter. Russell Investments Group Ltd. lifted its position in shares of Zimmer Biomet by 13.3% during the first quarter. Russell Investments Group Ltd. now owns 82,897 shares of the medical equipment provider's stock valued at $9,362,000 after buying an additional 9,758 shares during the last quarter. Cresset Asset Management LLC boosted its holdings in shares of Zimmer Biomet by 16.2% in the 1st quarter. Cresset Asset Management LLC now owns 43,219 shares of the medical equipment provider's stock valued at $4,902,000 after buying an additional 6,011 shares in the last quarter. Finally, Raymond James Financial Inc. grew its position in shares of Zimmer Biomet by 195.5% in the 1st quarter. Raymond James Financial Inc. now owns 594,097 shares of the medical equipment provider's stock worth $67,240,000 after buying an additional 393,077 shares during the last quarter. Institutional investors own 88.89% of the company's stock.</p>
<div class="lb-trans"><p>其他大型投资者最近也买卖了该公司的股票。Brighton Jones LLC 在第四季度购买了价值 204,000 美元的 Zimmer Biomet 新头寸。公共部门养老金投资委员会在第一季度将其在 Zimmer Biomet 的持股增加了 11.4%。公共部门养老金投资委员会目前持有 27,284 股这家医疗设备供应商的股票，价值 3,088,000 美元，此前在上个季度又购买了 2,789 股。Russell Investments Group Ltd. 在第一季度将其在 Zimmer Biomet 的持股增加了 13.3%。Russell Investments Group Ltd. 目前持有 82,897 股这家医疗设备供应商的股票，价值 9,362,000 美元，此前在上个季度又购买了 9,758 股。Cresset Asset Management LLC 在第一季度将其在 Zimmer Biomet 的持股增加了 16.2%。Cresset Asset Management LLC 目前持有 43,219 股这家医疗设备供应商的股票，价值 4,902,000 美元，此前在上个季度又购买了 6,011 股。最后，Raymond James Financial Inc. 在第一季度将其在 Zimmer Biomet 的持股增加了 195.5%。Raymond James Financial Inc. 目前持有 594,097 股这家医疗设备供应商的股票，价值 67,240,000 美元，此前在上个季度又购买了 393,077 股。机构投资者持有该公司 88.89% 的股票。</p>
</div><h2>Zimmer Biomet Trading Down 1.7%</h2>
<div class="lb-trans"><h2>Zimmer Biomet 股价下跌 1.7%</h2>
</div><p>NYSE:ZBH opened at $90.90 on Wednesday. The company has a market capitalization of $18.01 billion, a P/E ratio of 22.50, a PEG ratio of 2.43 and a beta of 0.61. The company has a current ratio of 2.43, a quick ratio of 1.39 and a debt-to-equity ratio of 0.59. Zimmer Biomet Holdings, Inc. has a 12 month low of $85.33 and a 12 month high of $114.44. The firm has a fifty day simple moving average of $95.35 and a 200-day simple moving average of $96.73.</p>
<div class="lb-trans"><p>周三，NYSE:ZBH 的开盘价为 90.90 美元。该公司的市值为 180.1 亿美元，市盈率为 22.50，市盈增长比率为 2.43，贝塔值为 0.61。该公司的流动比率为 2.43，速动比率为 1.39，债务与股本比率为 0.59。Zimmer Biomet Holdings, Inc. 的 12 个月低点为 85.33 美元，12 个月高点为 114.44 美元。该公司的 50 日简单移动平均线为 95.35 美元，200 日简单移动平均线为 96.73 美元。</p>
</div><ul>
<li>2 Robotic Surgery Stocks Challenging Intuitive Surgical's Lead</li>
</ul>
<div class="lb-trans"><ul>
<li>2 家机器人手术股票挑战 Intuitive Surgical 的领先地位</li>
</ul>
</div><p>Zimmer Biomet (NYSE:ZBH - Get Free Report) last issued its earnings results on Wednesday, November 5th. The medical equipment provider reported $1.90 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.88 by $0.02. Zimmer Biomet had a return on equity of 12.85% and a net margin of 10.05%.The company had revenue of $2 billion during the quarter, compared to analyst estimates of $2.01 billion. During the same quarter last year, the business posted $1.74 EPS. The firm's quarterly revenue was up 9.6% on a year-over-year basis. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. On average, equities research analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current year.</p>
<div class="lb-trans"><p>Zimmer Biomet (NYSE:ZBH - 获取免费报告) 最近在 11 月 5 日发布了其财报。这家医疗设备供应商报告本季度每股收益 (EPS) 为 1.90 美元，超出分析师一致预期的 1.88 美元，超出 0.02 美元。Zimmer Biomet 的股本回报率为 12.85%，净利润率为 10.05%。该公司在本季度的收入为 20 亿美元，而分析师预期为 20.1 亿美元。去年同期，该公司的每股收益为 1.74 美元。该公司的季度收入同比增长 9.6%。Zimmer Biomet 已将其 2025 财年的指导目标设定为 8.100-8.300 每股收益。平均而言，股票研究分析师预计 Zimmer Biomet Holdings, Inc. 本年度将发布 8.22 美元的每股收益。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>华尔街分析师观点</h2>
</div><p>Several equities research analysts have weighed in on ZBH shares. JPMorgan Chase &amp; Co. restated a &#34;neutral&#34; rating and issued a $100.00 target price (down from $115.00) on shares of Zimmer Biomet in a research note on Thursday, November 6th. UBS Group decreased their price objective on Zimmer Biomet from $96.00 to $88.00 and set a &#34;sell&#34; rating for the company in a report on Thursday, November 6th. Canaccord Genuity Group lowered their price objective on Zimmer Biomet from $101.00 to $93.00 and set a &#34;hold&#34; rating for the company in a research report on Monday, November 10th. Barclays dropped their target price on Zimmer Biomet from $112.00 to $105.00 and set an &#34;underweight&#34; rating on the stock in a research note on Wednesday, November 5th. Finally, Rothschild &amp; Co Redburn assumed coverage on Zimmer Biomet in a research note on Thursday, September 18th. They issued a &#34;buy&#34; rating and a $130.00 price target for the company. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, twelve have issued a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, Zimmer Biomet presently has an average rating of &#34;Hold&#34; and an average price target of $107.50.</p>
<div class="lb-trans"><p>几位股票研究分析师对 ZBH 股票发表了看法。摩根大通重申了对 Zimmer Biomet 的 &#34;中性&#34; 评级，并在 11 月 6 日的研究报告中将目标价下调至 100.00 美元（之前为 115.00 美元）。瑞银集团将 Zimmer Biomet 的目标价从 96.00 美元下调至 88.00 美元，并在 11 月 6 日的报告中对该公司给予了 &#34;卖出&#34; 评级。Canaccord Genuity Group 将 Zimmer Biomet 的目标价从 101.00 美元下调至 93.00 美元，并在 11 月 10 日的研究报告中对该公司给予了 &#34;持有&#34; 评级。巴克莱将 Zimmer Biomet 的目标价从 112.00 美元下调至 105.00 美元，并在 11 月 5 日的研究报告中对该股票给予了 &#34;减持&#34; 评级。最后，Rothschild &amp; Co Redburn 在 9 月 18 日的研究报告中开始覆盖 Zimmer Biomet。他们给予了该公司 &#34;买入&#34; 评级，并设定了 130.00 美元的目标价。一位股票研究分析师对该股票给予了强烈买入评级，七位给予了买入评级，十二位给予了持有评级，二位给予了卖出评级。根据 MarketBeat.com 的数据，Zimmer Biomet 目前的平均评级为 &#34;持有&#34;，平均目标价为 107.50 美元。</p>
</div><ul>
<li>Boston Scientific: Why This MedTech Giant Isn’t Slowing Down</li>
</ul>
<div class="lb-trans"><ul>
<li>波士顿科学：为什么这家医疗科技巨头不会放慢脚步</li>
</ul>
</div><p><strong>View Our Latest Report on ZBH</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 ZBH 的最新报告</strong></p>
</div><h2>Zimmer Biomet Company Profile</h2>
<div class="lb-trans"><h2>Zimmer Biomet 公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.</p>
<div class="lb-trans"><p>Zimmer Biomet Holdings, Inc. 及其子公司在全球范围内作为一家医疗技术公司运营。该公司设计、制造和销售骨科重建产品，如膝关节和髋关节产品；S.E.T. 产品，包括运动医学、生物制剂、足踝、四肢和创伤产品；颅面和胸部产品，包括面部和颅骨重建产品，以及固定和稳定胸部骨骼以促进心脏手术、创伤或胸部畸形后愈合或重建的产品。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推荐故事</h2>
</div><ul>
<li>Five stocks we like better than Zimmer Biomet</li>
<li>REIT Stocks - Best REIT Stocks to Add to Your Portfolio Today</li>
<li>AI Chips Can’t Exist Without These 2 Underrated Tech Giants</li>
<li>Stock Market Holidays 2022-2025 - Here’s When the NYSE and NASDAQ Will be Closed</li>
<li>Why Taiwan Semiconductor's 6.5% Dip Could Be a Smart Buy</li>
<li>How to Use Stock Screeners to Find Stocks</li>
<li>RTX Surges to Record Highs as Defense Orders Explode</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 Zimmer Biomet</li>
<li>REIT 股票 - 今天值得加入您投资组合的最佳 REIT 股票</li>
<li>AI 芯片离不开这两家被低估的科技巨头</li>
<li>2022-2025 年股市假期 - 纽约证券交易所和纳斯达克将何时关闭</li>
<li>为什么台湾半导体的 6.5% 下跌可能是一个明智的买入机会</li>
<li>如何使用股票筛选器寻找股票</li>
<li>RTX 在国防订单激增中飙升至创纪录高点</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding ZBH?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他对 ZBH 持有的对冲基金吗？</strong> 访问 HoldingsChannel.com 获取 Zimmer Biomet Holdings, Inc. (NYSE:ZBH - 免费报告) 的最新 13F 文件和内部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVpCSA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=ZBH"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒是由叙事科学技术和来自 MarketBeat 的金融数据生成的，旨在为读者提供最快的报道和公正的覆盖。请将任何关于此故事的问题或评论发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Zimmer Biomet Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Zimmer Biomet 吗？</h2>
</div><p>Before you consider Zimmer Biomet, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Zimmer Biomet 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zimmer Biomet wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Zimmer Biomet 并不在名单上。</p>
</div><p>While Zimmer Biomet currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Zimmer Biomet 目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

ST Germain D J Co. Inc. 购入了 14,058 股 Zimmer Biomet Holdings, Inc.的股票，股票代码为$ZBH